^
    5d
    RECHARGE 2: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P3, N=565, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Feb 2028 --> Oct 2027 | Trial primary completion date: Oct 2027 --> Jun 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Rhapsido (remibrutinib)
    7d
    CLOU064J12303B: A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa (2025-523259-72-00)
    P2/3, N=307, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Rhapsido (remibrutinib)
    14d
    CLOU064A2306B: A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial (2025-524078-40-00)
    P2/3, N=141, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Rhapsido (remibrutinib)
    19d
    RECHARGE-1: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) (clinicaltrials.gov)
    P3, N=588, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jan 2028 --> Oct 2027 | Trial primary completion date: Aug 2027 --> May 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Rhapsido (remibrutinib)
    21d
    CLOU064J12303B: A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa (2025-523259-72-00)
    P2/3, N=53, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Rhapsido (remibrutinib)
    21d
    CLOU064A2306B: A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial (2025-524078-40-00)
    P2/3, N=12, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Rhapsido (remibrutinib)
    24d
    Investigations of remibrutinib in models pertinent to multiple sclerosis. (PubMed, Neurotherapeutics)
    In T-bet+ memory B cells, remibrutinib decreased production of pro-inflammatory cytokines in culture and reduced expression of markers associated with T-bet+ memory B cells in mice. While Phase 3 clinical trial results in MS are awaited, the drug favorably affects inflammatory outcomes in MS models.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    Rhapsido (remibrutinib)
    30d
    RELIEF: A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients (clinicaltrials.gov)
    P=N/A, N=350, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Rhapsido (remibrutinib)
    1m
    Remibrutinib Open Label Roll-over Post-trial Access Protocol (clinicaltrials.gov)
    P3, N=212, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib)
    1m
    Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. (clinicaltrials.gov)
    P3, N=470, Active, not recruiting, Novartis Pharmaceuticals | N=218 --> 470
    Enrollment change
    |
    Rhapsido (remibrutinib)
    1m
    RECHARGE-1: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) (clinicaltrials.gov)
    P3, N=555, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting | N=205 --> 555
    Enrollment open • Enrollment change
    |
    Rhapsido (remibrutinib)
    1m
    RECHARGE 2: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P3, N=555, Recruiting, Novartis Pharmaceuticals | N=250 --> 555
    Enrollment change
    |
    Rhapsido (remibrutinib)